Back to Directory

Cambridge Cognition

CambridgeEast of England
Founded 2001
Digital cognitive assessment and CNS clinical trial software platform

Cambridge Cognition provides digital cognitive assessment and clinical trial technology for central nervous system drug development.

Its validated computerised tests measure memory, attention and executive function across conditions including Alzheimer's disease and schizophrenia.

The company also offers electronic clinical outcome assessments, AI-supported quality assurance for CNS scales, decentralised trial software and speech-based cognitive assessment through its Winterlight platform.

SoftwareNeurologyClinical ResearchAI & Machine Learning
Neurodegenerative DiseaseNeuropsychiatryPatient Recruitment

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Latest News

Company News2 Aug 2026

Cambridge Cognition Reports 16% H1 Revenue Growth, Clears Debt

Cambridge Cognition grew H1 2026 revenue 16% to £5.0m and fully repaid its borrowings, ending the period net cash positive. A £2.5m equity placing completed in July will fund CE marking in Europe and FDA 510(k) clearance in the US, paediatric product development, and speech recognition enhancements to its Winterlight platform.

Source: Investing.com UKRead source